Evidence map›Paper›PMID 36650430›Full record

ArticleBMC neuroscience2023

Evaluation of eGFP expression in the ChAT-eGFP transgenic mouse brain.

Rashmi Gamage, Laszlo Zaborszky, Gerald Münch, Erika Gyengesi

Open access · goldAbstract read
In one paragraph

Article in BMC neuroscience, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.6field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Rashmi GamagePharmacology Unit, Group of Pharmacology, School of Medicine, Western Sydney University, Penrith, NSW, 2751, Australia.
Laszlo ZaborszkyCenter for Molecular and Behavioral Neuroscience, Rutgers The State University of New Jersey, Newark, NJ, 07102, USA.
Gerald MünchPharmacology Unit, Group of Pharmacology, School of Medicine, Western Sydney University, Penrith, NSW, 2751, Australia.
Erika GyengesiPharmacology Unit, Group of Pharmacology, School of Medicine, Western Sydney University, Penrith, NSW, 2751, Australia. e.gyengesi@westernsydney.edu.au.
Western Sydney University · AURutgers, The State University of New Jersey · US

Funding

AFFERENT REGULATION OF CHOLINERGIC FOREBRAIN NEURONSR01NS023945 · NINDS · UNIVERSITY OF VIRGINIA CHARLOTTESVILLE · PI ZABORSZKY, LASZLO · 1986 to 2019
$6.5M
AFFERENT REGULATION OF CHOLINERGIC FOREBRAIN NEURONSRF1NS023945 · NINDS · RUTGERS THE STATE UNIV OF NJ NEWARK · PI ZABORSZKY, LASZLO · 2020 to 2020
$2.9M
NINDS NIH HHS R01 NS023945NINDS NIH HHS RF1 NS023945
6 · The paper itself

Abstract

backgroundA historically definitive marker for cholinergic neurons is choline acetyltransferase (ChAT), a synthesizing enzyme for acetylcholine, (ACh), which can be found in high concentrations in cholinergic neurons, both in the central and peripheral nervous systems. ChAT, is produced in the body of the neuron, transported to the nerve terminal (where its concentration is highest), and catalyzes the transfer of an acetyl group from the coenzyme acetyl-CoA to choline, yielding ACh. The creation of bacterial artificial chromosome (BAC) transgenic mice that express promoter-specific fluorescent reporter proteins (green fluorescent protein-[GFP]) provided an enormous advantage for neuroscience. Both in vivo and in vitro experimental methods benefited from the transgenic visualization of cholinergic neurons. Mice were created by adding a BAC clone into the ChAT locus, in which enhanced GFP (eGFP) is inserted into exon 3 at the ChAT initiation codon, robustly and supposedly selectively expressing eGFP in all cholinergic neurons and fibers in the central and peripheral nervous systems as well as in non-neuronal cells.

methodsThis project systematically compared the exact distribution of the ChAT-eGFP expressing neurons in the brain with the expression of ChAT by immunohistochemistry using mapping and also made comparisons with in situ hybridization (ISH).

resultsWe qualitatively described the distribution of ChAT-eGFP neurons in the mouse brain by comparing it with the distribution of immunoreactive neurons and ISH data, paying special attention to areas where the expression did not overlap, such as the cortex, striatum, thalamus and hypothalamus. We found a complete overlap between the transgenic expression of eGFP and the immunohistochemical staining in the areas of the cholinergic basal forebrain. However, in the cortex and hippocampus, we found small neurons that were only labeled with the antibody and not expressed eGFP or vice versa. Most importantly, we found no transgenic expression of eGFP in the lateral dorsal, ventral and dorsomedial tegmental nuclei cholinergic cells.

conclusionWhile the majority of the forebrain ChAT expression was aligned in the transgenic animals with immunohistochemistry, other areas of interest, such as the brainstem should be considered before choosing this particular transgenic mouse line.

Indexed as

Choline O-AcetyltransferaseProsencephalonAnimalsCholinergic AgentsGreen Fluorescent ProteinsMiceMice, TransgenicCholine O-AcetyltransferaseCholinergic AgentsGreen Fluorescent ProteinsAllen mouse brain atlasAntibody stainingBasal forebrain cholinergic neuronsChAT eGFPCholine acetyltransferaseImmunohistochemistryIn situ hybridizationTransgenic mice

Identifiers

PMID36650430
PMCPMC9847127
OpenAlexW4317039301

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.